was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We...was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We have corrected the scale bar in Fig.6 as follows.展开更多
This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above, the scale bar in Fig. 6A was wrong [1]. We missed a decimal point of the scale bar. The correct scal...This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above, the scale bar in Fig. 6A was wrong [1]. We missed a decimal point of the scale bar. The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm. We have corrected the scale bar in Fig. 6 as follows.展开更多
Abstract This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct ...Abstract This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We have corrected the scale bar in Fig.6 as follows.展开更多
Abstract This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct ...Abstract This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We have corrected the scale bar in Fig.6 as follows.展开更多
The prevalence of skin cancer is rising along with the rapid population aging in recent years.Traditional therapies,such as surgical treatment,radiotherapy,chemotherapy,photodynamic therapy,and immunotherapy,may accom...The prevalence of skin cancer is rising along with the rapid population aging in recent years.Traditional therapies,such as surgical treatment,radiotherapy,chemotherapy,photodynamic therapy,and immunotherapy,may accompany serious side effects,limiting their clinical benefits.According to the biological characteristics of skin cancer,we have already established two kinds of synergetic systems of photothermal therapy(microneedle)and chemotherapy,containing gold nanorods(GNR).Although the microneedle system exhibited great potential for skin cancer treatment,the system could be still improved further.So,we designed a near-infrared lightresponsive 5-fluorouracil(5-Fu)and indocyanine green(ICG)loaded monomethoxy-poly(ethylene glycol)-polycaprolactone(MPEG-PCL)nanoparticle(5-Fu-ICG-MPEG-PCL),and then 5-Fu-ICG-MPEG-PCL was integrated with a hyaluronic acid dissolvable microneedle system(HA MN)to get 5-Fu-ICG-MPEG-PCL loaded HA MN for treating skin cancers,including human epidermoid cancer and melanoma.In this system,hyaluronic acid,the microneedle carrier,possesses good skin penetration ability and is approved by FDA as a pharmaceutical adjuvant;5-Fu is recommended by FDA for skin cancer treatment;ICG,a photothermal agent,possesses a strong photothermal ability and is approved by FDA for its use in the human body.We hypothesized that 5-Fu-ICG-MPEG-PCL could be delivered by the dissolvable microneedle through the skin,and the release behavior of the drug in the nanoparticle could be controlled by near-infrared light for achieving a single-dose cure of skin cancer,improving the cure rate of skin cancer and providing a new idea and possibility for the clinical treatment of skin cancer.展开更多
Breast cancer has become the most commonly diagnosed cancer type in the world.A combination of chemotherapy and photothermal therapy(PTT) has emerged as a promising strategy for breast cancer therapy.However,the intri...Breast cancer has become the most commonly diagnosed cancer type in the world.A combination of chemotherapy and photothermal therapy(PTT) has emerged as a promising strategy for breast cancer therapy.However,the intricacy of precise delivery and the ability to initiate drug release in specific tumor sites remains a challenging puzzle.Therefore,to ensure that the therapeutic agents are synchronously delivered to the tumor site for their synergistic effect,a multifunctional nanoparticle system(PCRHNs) is developed,which is grafted onto the prussian blue nanoparticles(PB NPs) by reductionresponsive camptothecin(CPT) prodrug copolymer,and then modified with tumor-targeting peptide cyclo(Asp-D-Phe-Lys-Arg-Gly)(cRGD) and hyaluronic acid(HA).PCRHNs exhibited nano-sized structure with good monodispersity,high load efficiency of CPT,triggered CPT release in response to reduction environment,and excellent photothermal conversion under laser irradiation.Furthermore,PCRHNs can act as a photoacoustic imaging contrast agent-guided PTT.In vivo studies indicate that PCRHNs exhibited excellent bio compatibility,prolonged blood circulation,enhanced tumor accumulation,allow tumor-specific che mo-photo thermal therapy to achieve synergistic antitumor effects with reduced systemic toxicity.Moreover,hyperthermia-induced upregulation of heat shock protein 70 in the tumor cells could be inhibited by CPT.Collectively,PCRHNs may be a promising therapeutic way for breast cancer therapy.展开更多
mproving the eficacy of melanoma treatment remains an important global challenge.Here,we combined chemotherapy with protein tyrosine phosphatase nonreceptor type 2(Ptpn2)based immunotherapy in an effort to address thi...mproving the eficacy of melanoma treatment remains an important global challenge.Here,we combined chemotherapy with protein tyrosine phosphatase nonreceptor type 2(Ptpn2)based immunotherapy in an effort to address this challenge.Shorthairpin RNA(shRNA)targeting Ptpn2 was coencapsulated with doxorubicin(DOX)in the cell membrane of MI macrophages(MIHD@RPR).The prepared nanoparticles(NPs)were effectively phagocytosed by B16F10 cells and MI macrophages,but not by MOmacrophages.Hence,NPevasion from the reticuloendothelial system(RES)was improved and NPenrichment in tumor sites increased.MIHD@RPR can directly kill tumor cells and stimulate immunogenic cell death(ICD)by DOX and downregulate Ptpn2.It can promote Ml macrophage polarization and dendritic cell maturation and increase the proportion of CD8+T cells.MIHD@RPR killed and inhibited the growth of primary melanoma and lung metastatic tumor celis without harming the surrounding tssue.These findings establish MIHD@RPR as a safe multifunctional nanoparticle capable of effectively combining chemotherapy and gene immunotherapies against melanoma.展开更多
In recent years,Non-Hodgkin lymphoma(NHL)has been one of the most fast-growing malignant tumor diseases.NHL poses severe damages to physical health and a heavy burden to patients.Traditional therapies(chemotherapy or ...In recent years,Non-Hodgkin lymphoma(NHL)has been one of the most fast-growing malignant tumor diseases.NHL poses severe damages to physical health and a heavy burden to patients.Traditional therapies(chemotherapy or radiotherapy)bring some benefit to patients,but have severe adverse effects and do not prevent relapse.The relevance of emerging immunotherapy options(immune-checkpoint blockers or adoptive cellular methods)for NHL remains uncertain,and more intensive evaluations are needed.In this work,inspired by the idea of vaccination to promote an immune response to destroy tumors,we used a biomaterial-based strategy to improve a tumor cell-based vaccine and constructed a novel vaccine named Man-EG7/CH@CpG with antitumor properties.In this vaccine,natural tumor cells are used as a vector to load CpG-ODN,and following lethal irradiation,the formulations were decorated with mannose.The study of the characterization of the doubleimproved vaccine evidenced the enhanced ability of DCs targeting and improved immunocompetence,which displayed an antitumor function.In the lymphoma prevention model,the Man-EG7/CH@CpG vaccine restrained tumor formation with high efficiency.Furthermore,unlike the non-improved vaccine,the double-improved vaccine elicited an enhanced antitumor effect in the lymphoma treatment model.Next,to improve the moderate therapeutic effect of the mono-treatment method,we incorporated a chemotherapeutic drug(doxorubicin,DOX)into the process of vaccination and devised a combination regimen.Fortunately,a tumor inhibition rate of~85%was achieved via the combination therapy,which could not be achieved by mono-chemotherapy or mono-immunotherapy.In summary,the strategy presented here may provide a novel direction in the establishment of a tumor vaccine and is the basis for a prioritization scheme of immuno-chemotherapy in enhancing the therapeutic effect on NHL.展开更多
This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu...This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We have corrected the scale bar in Fig.6 as follows.展开更多
文摘was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We have corrected the scale bar in Fig.6 as follows.
文摘This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above, the scale bar in Fig. 6A was wrong [1]. We missed a decimal point of the scale bar. The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm. We have corrected the scale bar in Fig. 6 as follows.
文摘Abstract This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We have corrected the scale bar in Fig.6 as follows.
文摘Abstract This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].Erratum In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We have corrected the scale bar in Fig.6 as follows.
基金financially supported by the National Natural Science Foundation of China(No.31525009,31930067,31771096)West China Precision Medicine Industrial Technology Institutes(2018-CY02-00058-GX)+4 种基金National Key Research and Development Program of China(No.2017YFC1103502)1·3·5 project for disciplines of excellence,West China Hospital,Sichuan University(ZYGD18002)National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University(Z2018B06)Post-Doctor Research Project,West China Hospital,Sichuan University(2018HXBH043),China Postdoctoral Science Foundation(2019M653410)The Postdoctoral Innovation Talents Support Program(BX20180207).
文摘The prevalence of skin cancer is rising along with the rapid population aging in recent years.Traditional therapies,such as surgical treatment,radiotherapy,chemotherapy,photodynamic therapy,and immunotherapy,may accompany serious side effects,limiting their clinical benefits.According to the biological characteristics of skin cancer,we have already established two kinds of synergetic systems of photothermal therapy(microneedle)and chemotherapy,containing gold nanorods(GNR).Although the microneedle system exhibited great potential for skin cancer treatment,the system could be still improved further.So,we designed a near-infrared lightresponsive 5-fluorouracil(5-Fu)and indocyanine green(ICG)loaded monomethoxy-poly(ethylene glycol)-polycaprolactone(MPEG-PCL)nanoparticle(5-Fu-ICG-MPEG-PCL),and then 5-Fu-ICG-MPEG-PCL was integrated with a hyaluronic acid dissolvable microneedle system(HA MN)to get 5-Fu-ICG-MPEG-PCL loaded HA MN for treating skin cancers,including human epidermoid cancer and melanoma.In this system,hyaluronic acid,the microneedle carrier,possesses good skin penetration ability and is approved by FDA as a pharmaceutical adjuvant;5-Fu is recommended by FDA for skin cancer treatment;ICG,a photothermal agent,possesses a strong photothermal ability and is approved by FDA for its use in the human body.We hypothesized that 5-Fu-ICG-MPEG-PCL could be delivered by the dissolvable microneedle through the skin,and the release behavior of the drug in the nanoparticle could be controlled by near-infrared light for achieving a single-dose cure of skin cancer,improving the cure rate of skin cancer and providing a new idea and possibility for the clinical treatment of skin cancer.
基金supported by the National Natural Science Foundation of China (NSFC31930067, NSFC31771096, and NSFC31700869)the National Key Research and Development Program of China (2017YFC1103502)+1 种基金the 135 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYGD18002, China)the Post-Doctor Research Project, West China Hospital, Sichuan University (No.19HXBH099, China)。
文摘Breast cancer has become the most commonly diagnosed cancer type in the world.A combination of chemotherapy and photothermal therapy(PTT) has emerged as a promising strategy for breast cancer therapy.However,the intricacy of precise delivery and the ability to initiate drug release in specific tumor sites remains a challenging puzzle.Therefore,to ensure that the therapeutic agents are synchronously delivered to the tumor site for their synergistic effect,a multifunctional nanoparticle system(PCRHNs) is developed,which is grafted onto the prussian blue nanoparticles(PB NPs) by reductionresponsive camptothecin(CPT) prodrug copolymer,and then modified with tumor-targeting peptide cyclo(Asp-D-Phe-Lys-Arg-Gly)(cRGD) and hyaluronic acid(HA).PCRHNs exhibited nano-sized structure with good monodispersity,high load efficiency of CPT,triggered CPT release in response to reduction environment,and excellent photothermal conversion under laser irradiation.Furthermore,PCRHNs can act as a photoacoustic imaging contrast agent-guided PTT.In vivo studies indicate that PCRHNs exhibited excellent bio compatibility,prolonged blood circulation,enhanced tumor accumulation,allow tumor-specific che mo-photo thermal therapy to achieve synergistic antitumor effects with reduced systemic toxicity.Moreover,hyperthermia-induced upregulation of heat shock protein 70 in the tumor cells could be inhibited by CPT.Collectively,PCRHNs may be a promising therapeutic way for breast cancer therapy.
基金funded by the National Natural Science Foundation of China(31930067,31800797,31771096,81860543,and 31525009)the National Key Research and Development Program of China(2017YFC1103502)and 1-3-5 project for disciplines of excellence,West China Hospital,Sichuan University(ZYGD18002).
文摘mproving the eficacy of melanoma treatment remains an important global challenge.Here,we combined chemotherapy with protein tyrosine phosphatase nonreceptor type 2(Ptpn2)based immunotherapy in an effort to address this challenge.Shorthairpin RNA(shRNA)targeting Ptpn2 was coencapsulated with doxorubicin(DOX)in the cell membrane of MI macrophages(MIHD@RPR).The prepared nanoparticles(NPs)were effectively phagocytosed by B16F10 cells and MI macrophages,but not by MOmacrophages.Hence,NPevasion from the reticuloendothelial system(RES)was improved and NPenrichment in tumor sites increased.MIHD@RPR can directly kill tumor cells and stimulate immunogenic cell death(ICD)by DOX and downregulate Ptpn2.It can promote Ml macrophage polarization and dendritic cell maturation and increase the proportion of CD8+T cells.MIHD@RPR killed and inhibited the growth of primary melanoma and lung metastatic tumor celis without harming the surrounding tssue.These findings establish MIHD@RPR as a safe multifunctional nanoparticle capable of effectively combining chemotherapy and gene immunotherapies against melanoma.
基金financially supported by the National Natural Science Fund for Distinguished Young Scholar(NSFC31525009)National Natural Science Foundation of China(NSFC31930067,NSFC31771096,NSFC31871008,and NSFC31500809)+1 种基金the National Key Research and Development Program of China(2017YFC1103502)1·3·5 project for disciplines of excellence,West China Hospital,Sichuan University(ZYGD18002).
文摘In recent years,Non-Hodgkin lymphoma(NHL)has been one of the most fast-growing malignant tumor diseases.NHL poses severe damages to physical health and a heavy burden to patients.Traditional therapies(chemotherapy or radiotherapy)bring some benefit to patients,but have severe adverse effects and do not prevent relapse.The relevance of emerging immunotherapy options(immune-checkpoint blockers or adoptive cellular methods)for NHL remains uncertain,and more intensive evaluations are needed.In this work,inspired by the idea of vaccination to promote an immune response to destroy tumors,we used a biomaterial-based strategy to improve a tumor cell-based vaccine and constructed a novel vaccine named Man-EG7/CH@CpG with antitumor properties.In this vaccine,natural tumor cells are used as a vector to load CpG-ODN,and following lethal irradiation,the formulations were decorated with mannose.The study of the characterization of the doubleimproved vaccine evidenced the enhanced ability of DCs targeting and improved immunocompetence,which displayed an antitumor function.In the lymphoma prevention model,the Man-EG7/CH@CpG vaccine restrained tumor formation with high efficiency.Furthermore,unlike the non-improved vaccine,the double-improved vaccine elicited an enhanced antitumor effect in the lymphoma treatment model.Next,to improve the moderate therapeutic effect of the mono-treatment method,we incorporated a chemotherapeutic drug(doxorubicin,DOX)into the process of vaccination and devised a combination regimen.Fortunately,a tumor inhibition rate of~85%was achieved via the combination therapy,which could not be achieved by mono-chemotherapy or mono-immunotherapy.In summary,the strategy presented here may provide a novel direction in the establishment of a tumor vaccine and is the basis for a prioritization scheme of immuno-chemotherapy in enhancing the therapeutic effect on NHL.
文摘This is an erratum to our published paper,the scale bar in Fig.6A was wrong[1].In the paper mentioned above,the scale bar in Fig.6A was wrong[1].We missed a decimal point of the scale bar.The correct scale bar of 5-Fu-ICG-MPEG-PCL@HA MN should be 1.00 mm instead of 100 mm.We have corrected the scale bar in Fig.6 as follows.
